Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity

This commentary provides the authors’ perspective on the article “Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial,” which has recently been published in The Lancet Oncology.

Detalles Bibliográficos
Autores principales: Madan, Ravi A, Heery, Christopher R., Gulley, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494633/
https://www.ncbi.nlm.nih.gov/pubmed/23170267
http://dx.doi.org/10.4161/onci.20591
_version_ 1782249419336318976
author Madan, Ravi A
Heery, Christopher R.
Gulley, James L.
author_facet Madan, Ravi A
Heery, Christopher R.
Gulley, James L.
author_sort Madan, Ravi A
collection PubMed
description This commentary provides the authors’ perspective on the article “Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial,” which has recently been published in The Lancet Oncology.
format Online
Article
Text
id pubmed-3494633
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-34946332012-11-20 Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity Madan, Ravi A Heery, Christopher R. Gulley, James L. Oncoimmunology Author's View This commentary provides the authors’ perspective on the article “Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial,” which has recently been published in The Lancet Oncology. Landes Bioscience 2012-10-01 /pmc/articles/PMC3494633/ /pubmed/23170267 http://dx.doi.org/10.4161/onci.20591 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Madan, Ravi A
Heery, Christopher R.
Gulley, James L.
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
title Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
title_full Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
title_fullStr Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
title_full_unstemmed Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
title_short Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
title_sort combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494633/
https://www.ncbi.nlm.nih.gov/pubmed/23170267
http://dx.doi.org/10.4161/onci.20591
work_keys_str_mv AT madanravia combinationofvaccineandimmunecheckpointinhibitorissafewithencouragingclinicalactivity
AT heerychristopherr combinationofvaccineandimmunecheckpointinhibitorissafewithencouragingclinicalactivity
AT gulleyjamesl combinationofvaccineandimmunecheckpointinhibitorissafewithencouragingclinicalactivity

Ejemplares similares